Pfizer (PFE) Liabilities and Shareholders Equity (2009 - 2026)

Pfizer (PFE) has reported Liabilities and Shareholders Equity for 18 consecutive years, with $208.0 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.01% year-over-year to $208.0 billion; the TTM figure through Mar 2026 stood at $830.8 billion (down 3.0% YoY), while the FY2025 annual figure was $208.0 billion, down 2.35% from the prior year.
• Liabilities and Shareholders Equity steadied at $208.0 billion in Q1 2026 per PFE's latest filing, from $208.0 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $227.0 billion in Q4 2023 and bottomed at $41.1 billion in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $188.9 billion across 5 years, with a median of $208.0 billion in 2025.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity fell 11.22% — and 2024, when it surged 412.44%.
• Pfizer's Liabilities and Shareholders Equity stood at $197.0 billion in 2022, then grew by 15.23% to $227.0 billion in 2023, then dropped by 6.17% to $213.0 billion in 2024, then declined by 2.35% to $208.0 billion in 2025, then changed by 0.0% to $208.0 billion in 2026.
• Business Quant data shows PFE's Liabilities and Shareholders Equity at $208.0 billion in Q1 2026, $208.0 billion in Q4 2025, and $208.7 billion in Q3 2025.